Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Andrew M Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Irene Helenowski, PhD, Michael Millenson, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2013) 122 (21): 1807.

https://doi.org/10.1182/blood.V122.21.1807.1807

Published: 2013

Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2012) 120 (21): 1642.

https://doi.org/10.1182/blood.V120.21.1642.1642

Published: 2012

Journal Articles

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

Francine M. Foss, MD, Kenneth R. Carson, MD, Lauren Pinter-Brown, MD, Steven M. Horwitz, MD, Steven T. Rosen, MD, FRCPA, Barbara Pro, MD, Massimo Federico, MD, Christian Gisselbrecht, MD, Eric D. Hsi, MD

Blood (2012) 120 (21): 1614.

https://doi.org/10.1182/blood.V120.21.1614.1614

Published: 2012

Journal Articles

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

Eric D. Hsi, MD, Aaron M. Gruver, MD, PhD, Francine M. Foss, MD, Kenneth R. Carson, MD, Lauren Pinter-Brown, MD, Steven M. Horwitz, MD, Steven T. Rosen, MD, FRCPA, Barbara Pro, MD, Massimo Federico, MD, Christian Gisselbrecht, MD

Blood (2012) 120 (21): 4263.

https://doi.org/10.1182/blood.V120.21.4263.4263

Published: 2012

Journal Articles

Targeting Glycolysis and Compensatory Mitochondrial Metabolism in Multiple Myeloma with FDA Approved Ritonavir and Metformin Via Synthetic Lethality

Kehinde U. A. Adekola, M.B.B.S, Maylyn Martinez, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD

Blood (2012) 120 (21): 4016.

https://doi.org/10.1182/blood.V120.21.4016.4016

Published: 2012

Journal Articles

Targeting Glucose Metabolism and Compensatory Metabolic Resistance in Chronic Lymphocytic Leukemia

Kehinde U.A. Adekola, MBBS, Vivian Liu, Shuo Ma, MD, PhD, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD

Blood (2012) 120 (21): 1801.

https://doi.org/10.1182/blood.V120.21.1801.1801

Published: 2012

Journal Articles

Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.

Blood (2012) 120 (21): 2728.

https://doi.org/10.1182/blood.V120.21.2728.2728

Published: 2012

Journal Articles

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Kyriakos P Papadopoulos, MD, Peter Lee, MD, PhD, Seema Singhal, MD, Joseph R. Holahan, MD, David H. Vesole, MD, PhD, Steven T. Rosen, MD, FRCPA, Lori Kunkel, MD, Alison L. Hannah, MD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 2930.

https://doi.org/10.1182/blood.V118.21.2930.2930

Published: 2011

Journal Articles

Myeloma Exhibits Dependence on Atypical Glucose Transporters: Targeting MCL-1 Through GLUT4 Inhibition

Mala Shanmugam, PhD, Javelin C Cheng, MS, Samuel K McBrayer, Steven T. Rosen, MD, FRCPA

Blood (2011) 118 (21): 1850.

https://doi.org/10.1182/blood.V118.21.1850.1850

Published: 2011

Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD

Blood (2011) 118 (21): 1646.

https://doi.org/10.1182/blood.V118.21.1646.1646

Published: 2011

Journal Articles

Predictors of Response to Salvage Therapy for Advanced Chronic Lymphocytic Leukemia (ECOG Protocol 2903)

Neil E. Kay, Haesook Kim, PhD, Sanford Kempin, MD, Steven T. Rosen, MD, FRCPA, Hillard Lazarus, Diane F. Jelinek, PhD, Martin S. Tallman, MD

Blood (2010) 116 (21): 2463.

https://doi.org/10.1182/blood.V116.21.2463.2463

Published: 2010

NARROW

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

Targeting Glycolysis and Compensatory Mitochondrial Metabolism in Multiple Myeloma with FDA Approved Ritonavir and Metformin Via Synthetic Lethality

Targeting Glucose Metabolism and Compensatory Metabolic Resistance in Chronic Lymphocytic Leukemia

Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Myeloma Exhibits Dependence on Atypical Glucose Transporters: Targeting MCL-1 Through GLUT4 Inhibition

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Predictors of Response to Salvage Therapy for Advanced Chronic Lymphocytic Leukemia (ECOG Protocol 2903)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only